LMAT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
LeMaitre Vascular Inc (LMAT) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company's strong financial performance, positive analyst sentiment, and growth potential in international markets outweigh the overbought technical indicators and hedge fund selling trends. The recent dividend increase and robust Q4 results further support a long-term investment decision.
The stock is in a strong bullish trend with MACD positively expanding above 0, RSI at 93.191 indicating overbought conditions, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). Key resistance levels are at R1: 109.215 and R2: 116.282, with the current price nearing these levels.
Q4 2025 financials showed strong growth: Revenue up 15.68% YoY, Net Income up 39.32% YoY, and EPS up 38.78% YoY.
Dividend increase from $0.20 to $0.25 per share.
Analyst confidence in management's long-term strategy and increased price target to $
Anticipated $10 million in international sales for ArteGraft in 2026.
Hedge funds are selling, with a 398.42% increase in selling activity last quarter.
Officer George LeMaitre plans to sell $10.35 million worth of shares, which may signal insider profit-taking.
RSI indicates overbought conditions, suggesting a potential short-term pullback.
In Q4 2025, LeMaitre Vascular reported strong financial growth: Revenue increased to $64.45 million (up 15.68% YoY), Net Income increased to $15.58 million (up 39.32% YoY), EPS increased to $0.68 (up 38.78% YoY), and Gross Margin improved to 71.66% (up 3.47% YoY).
Analysts maintain an Outperform rating with a raised price target of $118, citing strong top- and bottom-line performance, management's pricing strategy, operating leverage, and international growth potential.
